Kimball, Allison http://orcid.org/0000-0002-6750-644X
Dichtel, Laura E.
Yuen, Kevin C. J.
Woodmansee, Whitney W.
Haines, Melanie S.
Nachtigall, Lisa B.
Swearingen, Brooke
Jones, Pamela
Tritos, Nicholas A.
Sharpless, Julie L.
Kaiser, Ursula B.
Gerweck, Anu
Miller, Karen K.
Funding for this research was provided by:
Endocrine Society (Acromegaly Clinical Research Fellowship Award)
National Institutes of Health (T32 DK007028, K24 HL092902, K23DK115903, K23 DK113220)
National Center for Advancing Translational Sciences (1UL1TR001102, 8 UL1 TR000170)
National Center for Research Resources (1 UL1 RR025758)
Article History
Accepted: 5 April 2022
First Online: 27 April 2022
Declarations
:
: LED has received drug donation from Pfizer for an investigator-initiated study. WWW has participated as a clinical trial investigator for Chiasma. LBN has received grant support/investigator funding from Ipsen and Chiasma and serves as a consultant on an advisory board for Pfizer and Chiasma. BS has equity in Pfizer and Amgen. UBK served as a consultant on advisory boards for Novo Nordisk and Acerus. KKM has received grant support for investigator-initiated studies from Amgen and drug donation from Pfizer for an investigated-initiated study and has equity in GE, Bristol-Myers Squibb, Becton Dickinson, and Boston Scientific. The other authors have no conflicts of interest to disclose.
: Approval was obtained from the Massachusetts General Hospital Institutional Review Board. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.